Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
Barbara De MoerlooseArdine ReedijkGeertruida H de BockTim LammensValerie de HaasBarbara DenysLaurence DedekenMarry M van den Heuvel-EibrinkMaroeska Te LooAnne UyttebroeckAn Van DammeJutte Van der Werff-Ten BoschJozsef ZsirosGertjan KaspersEveline de BontPublished in: Pediatric blood & cancer (2019)
DB AML-01 response-guided therapy results in a favorable OS, particularly for children with CBF leukemia, children younger than 10 years or with initial WBC counts below 100 × 109 /L. Outcome of patients with FLT3-ITD/NPM1-WT remains poor and warrants alternative treatment strategies.